Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people . At present, non-surgical treatment methods are often used, such as radiofrequency ablation (RFA), Transcatheter arterial chemoembolization (TACE), radiation therapy, and systemic anti-tumor therapy. However, whether it is surgical treatment or non-surgical treatment, commonly used liver cancer related biomarkers in clinical practice during the evaluation of treatment efficacy or regular follow-up of patients include AFP, AFP-L3%, DCP, etc. , but there are no reports on whether AKR1B10 can be used for the efficacy evaluation of these treatment methods.Therefore, this project aims to explore the clinical value of AKR1B10 in evaluating the efficacy of liver cancer treatment.
- EligibilityCriteria: Inclusion Criteria:  age between 18 and 80 diagnosis of HCC according the AASLD criteria TACE is planned resection is impossible No significant underlying medical illness affecting patient's survival Patients available for regular follow-up according to the study protocol  Exclusion Criteria:  Previous history of other tumors; Combined with other tumors; Received external treatment before admission; Patients who have received blood transfusions within one month; The patient was unable to participate in this study for other reasons. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: All participants have signed an informed consent form, agreeing that their samples and related information can be used for all medical studies. - SamplingMethod: Probability Sample